Pensionfund Sabic Has $1.90 Million Holdings in Pfizer Inc. $PFE

Pensionfund Sabic lowered its stake in Pfizer Inc. (NYSE:PFE) by 11.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,000 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the period. Pensionfund Sabic’s holdings in Pfizer were worth $1,901,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Pfizer in the first quarter worth about $4,945,000. Voya Investment Management LLC increased its stake in shares of Pfizer by 5.0% in the first quarter. Voya Investment Management LLC now owns 1,677,705 shares of the biopharmaceutical company’s stock worth $42,513,000 after purchasing an additional 80,646 shares during the period. Howe & Rusling Inc. increased its stake in shares of Pfizer by 8.9% in the first quarter. Howe & Rusling Inc. now owns 28,800 shares of the biopharmaceutical company’s stock worth $730,000 after purchasing an additional 2,345 shares during the period. Lynx Investment Advisory increased its stake in shares of Pfizer by 53.3% in the first quarter. Lynx Investment Advisory now owns 47,782 shares of the biopharmaceutical company’s stock worth $1,211,000 after purchasing an additional 16,621 shares during the period. Finally, First Hawaiian Bank increased its stake in shares of Pfizer by 6.9% in the first quarter. First Hawaiian Bank now owns 54,455 shares of the biopharmaceutical company’s stock worth $1,380,000 after purchasing an additional 3,531 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. HSBC dropped their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Bank of America lifted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Trading Down 3.8%

Shares of PFE opened at $23.91 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. The stock’s 50-day moving average price is $24.79 and its 200 day moving average price is $24.30.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.